China SXT Pharmaceuticals, Inc. (SXTC)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$2.08−13.69%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.7M
- 52-week range
- $1.56 – $83,760.00
- 52-week change
- −99.99%
- EPS (trailing)
- −$730.40
Fiscal year to Mar 2026
- Revenue
- $1.1M (−34.63%)
- Net income
- −$6.2M
- Operating margin
- −625.9%
- Diluted EPS
- −$9.13
From the company’s annual report on SEC EDGAR.
About China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Headquarters: Taizhou, China · 56 employees · sxtchina.com